Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2028

Conditions

Advanced Colorectal Cancer

Interventions

DRUG

Defactinib

Given by PO

DRUG

Cetuximab

Given by IV

DRUG

Avutometinib

Given by PO

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER